{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T09:10:54Z","timestamp":1778231454183,"version":"3.51.4"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s13300-025-01836-2","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:04:39Z","timestamp":1770879879000},"page":"685-709","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Safety of SGLT2 Versus DPP4 Inhibitors in Patients with Type\u00a02 Diabetes: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3092-0905","authenticated-orcid":false,"given":"Yue","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuying","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqiong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9169-2641","authenticated-orcid":false,"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4964-2289","authenticated-orcid":false,"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"2","key":"1836_CR1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrendo.2017.151","volume":"14","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type\u00a02 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88\u201398. https:\/\/doi.org\/10.1038\/nrendo.2017.151.","journal-title":"Nat Rev Endocrinol"},{"key":"1836_CR2","doi-asserted-by":"publisher","unstructured":"Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type\u00a02 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154(9):602\u2013613. https:\/\/doi.org\/10.7326\/0003-4819-154-9-201105030-00336. (Published correction appears in Ann Intern Med. 2011 Jul 05;155(1):67\u20138. https:\/\/doi.org\/10.7326\/0003-4819-155-1-201107050-00016\n.)","DOI":"10.7326\/0003-4819-154-9-201105030-00336"},{"issue":"3","key":"1836_CR3","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","volume":"103","author":"S Geerlings","year":"2014","unstructured":"Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014;103(3):373\u201381. https:\/\/doi.org\/10.1016\/j.diabres.2013.12.052.","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"1836_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41574-018-0098-9","volume":"15","author":"NG Forouhi","year":"2019","unstructured":"Forouhi NG, Wareham NJ. Epidemiology of diabetes. Nat Rev Endocrinol. 2019;15(2):63\u20139. https:\/\/doi.org\/10.1038\/s41574-018-0098-9.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"1836_CR5","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.2337\/dc23-S009","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023;46(1):S140\u201357. https:\/\/doi.org\/10.2337\/dc23-S009.","journal-title":"Diabetes Care"},{"key":"1836_CR6","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of care in diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S207\u201338. https:\/\/doi.org\/10.2337\/dc25-S010.","DOI":"10.2337\/dc25-S010"},{"issue":"22","key":"1836_CR7","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type\u00a02 diabetes. N Engl J Med. 2015;373(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"issue":"4","key":"1836_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type\u00a02 diabetes. N Engl J Med. 2019;380(4):347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med"},{"key":"1836_CR9","doi-asserted-by":"publisher","unstructured":"Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type\u00a02 diabetes. N Engl J Med. 2015;373(3):232\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1501352. (Published correction appears in N Engl J Med. 2015 Aug 6;373(6):586. https:\/\/doi.org\/10.1056\/NEJMx150029.)","DOI":"10.1056\/NEJMoa1501352"},{"issue":"4","key":"1836_CR10","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s13300-018-0445-x","volume":"9","author":"C Mathieu","year":"2018","unstructured":"Mathieu C, Catrinoiu D, Ranetti AE, et al. Characterization of the open-label lead-in period of two randomized controlled phase\u00a03 trials evaluating dapagliflozin, saxagliptin, and metformin in type\u00a02 diabetes. Diabetes Ther. 2018;9(4):1703\u201311. https:\/\/doi.org\/10.1007\/s13300-018-0445-x.","journal-title":"Diabetes Ther"},{"issue":"1","key":"1836_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02149-7","volume":"23","author":"M Nagao","year":"2024","unstructured":"Nagao M, Sasaki J, Tanimura-Inagaki K, et al. Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type\u00a02 diabetes: the SUCRE study. Cardiovasc Diabetol. 2024;23(1):56. https:\/\/doi.org\/10.1186\/s12933-024-02149-7.","journal-title":"Cardiovasc Diabetol"},{"key":"1836_CR12","doi-asserted-by":"publisher","unstructured":"Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type\u00a02 diabetes. Diabetes Care. 2015;38(3):394\u2013402. https:\/\/doi.org\/10.2337\/dc14-2365. (Published correction appears in Diabetes Care. 2015 Jun;38(6):1173. https:\/\/doi.org\/10.2337\/dc15-er06a.)","DOI":"10.2337\/dc14-2365"},{"key":"1836_CR13","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. Published 2021 Mar 29. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"1836_CR14","doi-asserted-by":"publisher","unstructured":"Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008. https:\/\/doi.org\/10.1136\/bmj.j4008.","DOI":"10.1136\/bmj.j4008"},{"key":"1836_CR15","doi-asserted-by":"publisher","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","DOI":"10.1136\/bmj.d5928"},{"issue":"9","key":"1836_CR16","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1111\/dom.15717","volume":"26","author":"KA Han","year":"2024","unstructured":"Han KA, Hwang YC, Moon SJ, et al. Dual add-on therapy of gemigliptin and dapagliflozin in patients with type\u00a02 diabetes inadequately controlled with metformin alone: the SOLUTION 2 study. Diabetes Obes Metab. 2024;26(9):3743\u201352. https:\/\/doi.org\/10.1111\/dom.15717.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1836_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2020.08.001","volume":"47","author":"SC Liu","year":"2021","unstructured":"Liu SC, Lee CC, Chuang SM, Sun FJ, Zeng YH. Comparison of efficacy and safety of empagliflozin vs linagliptin added to premixed insulin in patients with uncontrolled type\u00a02 diabetes: a randomized, open-label study. Diabetes Metab. 2021;47(3):101184. https:\/\/doi.org\/10.1016\/j.diabet.2020.08.001.","journal-title":"Diabetes Metab"},{"issue":"2","key":"1836_CR18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/dom.13882","volume":"22","author":"SH Kwak","year":"2020","unstructured":"Kwak SH, Hwang YC, Won JC, et al. Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type\u00a02 diabetes: a randomized, open-label, active-controlled, 12-week study (STABLE II study). Diabetes Obes Metab. 2020;22(2):173\u201381. https:\/\/doi.org\/10.1111\/dom.13882.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1836_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0977-z","volume":"19","author":"A Fuchigami","year":"2020","unstructured":"Fuchigami A, Shigiyama F, Kitazawa T, et al. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type\u00a02 diabetes: a prospective, randomized study (DIVERSITY-CVR). Cardiovasc Diabetol. 2020;19(1):1. https:\/\/doi.org\/10.1186\/s12933-019-0977-z.","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"1836_CR20","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1111\/dom.13795","volume":"21","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Perl S, Johnsson E, Garc\u00eda-S\u00e1nchez R, Jacob S. Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type\u00a02 diabetes. Diabetes Obes Metab. 2019;21(9):2152\u201362. https:\/\/doi.org\/10.1111\/dom.13795.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1836_CR21","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1111\/dom.13473","volume":"20","author":"R Scott","year":"2018","unstructured":"Scott R, Morgan J, Zimmer Z, et al. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type\u00a02 diabetes mellitus and mild renal insufficiency: the CompoSIT-R study. Diabetes Obes Metab. 2018;20(12):2876\u201384. https:\/\/doi.org\/10.1111\/dom.13473.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1836_CR22","doi-asserted-by":"publisher","first-page":"424","DOI":"10.20945\/2359-3997000000056","volume":"62","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock J, Mathieu C, Chen H, Garcia-Sanchez R, Saraiva GL. Dapagliflozin versus saxagliptin as add-on therapy in patients with type\u00a02 diabetes inadequately controlled with metformin. Arch Endocrinol Metab. 2018;62(4):424\u201330. https:\/\/doi.org\/10.20945\/2359-3997000000056.","journal-title":"Arch Endocrinol Metab"},{"issue":"7","key":"1836_CR23","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s12325-018-0724-y","volume":"35","author":"RA DeFronzo","year":"2018","unstructured":"DeFronzo RA, Lee C, Kohler S. Safety and tolerability of combinations of empagliflozin and linagliptin in patients with type\u00a02 diabetes: pooled data from two randomized controlled trials. Adv Ther. 2018;35(7):1009\u201322. https:\/\/doi.org\/10.1007\/s12325-018-0724-y.","journal-title":"Adv Ther"},{"issue":"5","key":"1836_CR24","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/dom.13194","volume":"20","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, Eldor R, Raji A, et al. Ertugliflozin plus sitagliptin versus either individual agent over 52\u00a0weeks in patients with type\u00a02 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2018;20(5):1111\u201320. https:\/\/doi.org\/10.1111\/dom.13194.","journal-title":"Diabetes Obes Metab"},{"key":"1836_CR25","doi-asserted-by":"publisher","unstructured":"DeFronzo RA, Lewin A, Patel S, et al. Erratum. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type\u00a02 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38:384\u201393. Diabetes Care. 2015;38(6):1173. https:\/\/doi.org\/10.2337\/dc15-er06.","DOI":"10.2337\/dc15-er06"},{"issue":"3","key":"1836_CR26","doi-asserted-by":"publisher","first-page":"376","DOI":"10.2337\/dc14-1142","volume":"38","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type\u00a02 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38(3):376\u201383. https:\/\/doi.org\/10.2337\/dc14-1142.","journal-title":"Diabetes Care"},{"issue":"3","key":"1836_CR27","doi-asserted-by":"publisher","first-page":"740","DOI":"10.2337\/dc13-0467","volume":"37","author":"SA Jabbour","year":"2014","unstructured":"Jabbour SA, Hardy E, Sugg J, Parikh S, Study 10 Group. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37(3):740\u201350. https:\/\/doi.org\/10.2337\/dc13-0467.","journal-title":"Diabetes Care"},{"issue":"9","key":"1836_CR28","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s13300-023-01438-w","volume":"14","author":"M Sugawara","year":"2023","unstructured":"Sugawara M, Fukuda M, Sakuma I, et al. Overall efficacy and safety of sodium-glucose cotransporter\u00a02 inhibitor luseogliflozin versus dipeptidyl-peptidase 4 inhibitors: multicenter, open-label, randomized-controlled trial (J-SELECT study). Diabetes Ther. 2023;14(9):1517\u201335. https:\/\/doi.org\/10.1007\/s13300-023-01438-w.","journal-title":"Diabetes Ther"},{"issue":"6","key":"1836_CR29","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s13300-024-01575-w","volume":"15","author":"M Fukuda","year":"2024","unstructured":"Fukuda M, Sakuma I, Wakasa Y, et al. Effect of luseogliflozin, a sodium-glucose cotransporter\u00a02 inhibitor, and dipeptidyl-peptidase 4 inhibitors on the quality-of-life and treatment satisfaction of patients with type\u00a02 diabetes mellitus: a subanalysis of a multicenter, open-label, randomized-controlled trial (J-SELECT study). Diabetes Ther. 2024;15(6):1403\u201316. https:\/\/doi.org\/10.1007\/s13300-024-01575-w.","journal-title":"Diabetes Ther"},{"issue":"3","key":"1836_CR30","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/dom.14288","volume":"23","author":"M Kitazawa","year":"2021","unstructured":"Kitazawa M, Katagiri T, Suzuki H, et al. A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type\u00a02 diabetes combined with metformin: the N-ISM study. Diabetes Obes Metab. 2021;23(3):811\u201321. https:\/\/doi.org\/10.1111\/dom.14288.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"1836_CR31","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1111\/dom.15056","volume":"25","author":"SM Kang","year":"2023","unstructured":"Kang SM, Yun HM, Sohn M, Lim S. Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type\u00a02 diabetes treated with sulphonylurea and metformin: IVS study. Diabetes Obes Metab. 2023;25(7):1922\u201331. https:\/\/doi.org\/10.1111\/dom.15056.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1836_CR32","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/bcp.13903","volume":"85","author":"A Phrommintikul","year":"2019","unstructured":"Phrommintikul A, Wongcharoen W, Kumfu S, et al. Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study. Br J Clin Pharmacol. 2019;85(6):1337\u201347. https:\/\/doi.org\/10.1111\/bcp.13903.","journal-title":"Br J Clin Pharmacol"},{"key":"1836_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1412553","volume":"15","author":"M Shimoda","year":"2024","unstructured":"Shimoda M, Katakura Y, Mashiko A, et al. Comparison of protective effects of teneligliptin and luseogliflozin on pancreatic \u03b2-cell function: randomized, parallel-group, multicenter, open-label study (SECRETE-I study). Front Endocrinol (Lausanne). 2024;15:1412553. https:\/\/doi.org\/10.3389\/fendo.2024.1412553.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"1836_CR34","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1007\/s13300-020-00941-8","volume":"11","author":"H Ishii","year":"2020","unstructured":"Ishii H, Nakajima H, Kamei N, et al. Quality-of-life comparison of dapagliflozin versus dipeptidyl peptidase 4 inhibitors in patients with type\u00a02 diabetes mellitus: a randomized controlled trial (J-BOND study). Diabetes Ther. 2020;11(12):2959\u201377. https:\/\/doi.org\/10.1007\/s13300-020-00941-8.","journal-title":"Diabetes Ther"},{"key":"1836_CR35","doi-asserted-by":"publisher","unstructured":"Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type\u00a02 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36(9):2508\u20132515. https:\/\/doi.org\/10.2337\/dc12-2491. (Published correction appears in Diabetes Care. 2013 Dec;36(12):4172.)","DOI":"10.2337\/dc12-2491"},{"issue":"7","key":"1836_CR36","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1111\/dom.15596","volume":"26","author":"Y Wang","year":"2024","unstructured":"Wang Y, Jiang C, Dong X, et al. Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type\u00a02 diabetes inadequately controlled with metformin: a multicentre, randomized, double-blind, active-controlled, phase\u00a03 trial. Diabetes Obes Metab. 2024;26(7):2774\u201386. https:\/\/doi.org\/10.1111\/dom.15596.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1836_CR37","doi-asserted-by":"publisher","first-page":"243","DOI":"10.18295\/squmj.1.2024.006","volume":"24","author":"V Sharma","year":"2024","unstructured":"Sharma V, Chawla S, Garg S, Singh B. Efficacy and safety of vildagliptin and remogliflozin as add-on therapy to metformin in patients of type\u00a02 diabetes mellitus: an open-label comparative study. Sultan Qaboos Univ Med J. 2024;24(2):243\u20139. https:\/\/doi.org\/10.18295\/squmj.1.2024.006.","journal-title":"Sultan Qaboos Univ Med J"},{"key":"1836_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110872","volume":"203","author":"JH Hong","year":"2023","unstructured":"Hong JH, Moon JS, Seong K, Lim S. Comparison of therapeutic efficacy and safety of sitagliptin, dapagliflozin, or lobeglitazone adjunct therapy in patients with type\u00a02 diabetes mellitus inadequately controlled on sulfonylurea and metformin: third agent study. Diabetes Res Clin Pract. 2023;203:110872. https:\/\/doi.org\/10.1016\/j.diabres.2023.110872.","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"1836_CR39","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1111\/dom.15089","volume":"25","author":"K Takuma","year":"2023","unstructured":"Takuma K, Fuchigami A, Shigiyama F, Kumashiro N, Hirose T. Comparison of the effects of sitagliptin and dapagliflozin on time in range in Japanese patients with type\u00a02 diabetes stratified by body mass index: a sub-analysis of the DIVERSITY-CVR study. Diabetes Obes Metab. 2023;25(8):2131\u201341. https:\/\/doi.org\/10.1111\/dom.15089.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1836_CR40","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/dom.15006","volume":"25","author":"S Hiruma","year":"2023","unstructured":"Hiruma S, Shigiyama F, Kumashiro N. Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type\u00a02 diabetes with non-alcoholic fatty liver disease: a prospective randomized study. Diabetes Obes Metab. 2023;25(6):1576\u201388. https:\/\/doi.org\/10.1111\/dom.15006.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1836_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01228-3","volume":"20","author":"S Hiruma","year":"2021","unstructured":"Hiruma S, Shigiyama F, Hisatake S, et al. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type\u00a02 diabetes: the ASSET study. Cardiovasc Diabetol. 2021;20(1):32. https:\/\/doi.org\/10.1186\/s12933-021-01228-3.","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"1836_CR42","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1007\/s13300-020-00907-w","volume":"11","author":"A Raji","year":"2020","unstructured":"Raji A, Xu ZJ, Lam RLH, O\u2019Neill EA, Kaufman KD, Engel SS. Efficacy and safety of sitagliptin compared with dapagliflozin in people \u2265\u00a065\u00a0years old with type\u00a02 diabetes and mild renal insufficiency. Diabetes Ther. 2020;11(10):2419\u201328. https:\/\/doi.org\/10.1007\/s13300-020-00907-w.","journal-title":"Diabetes Ther"},{"issue":"10","key":"1836_CR43","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1111\/dom.13801","volume":"21","author":"YD Halvorsen","year":"2019","unstructured":"Halvorsen YD, Lock JP, Zhou W, Zhu F, Freeman MW. A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type\u00a02 diabetes in adults. Diabetes Obes Metab. 2019;21(10):2248\u201356. https:\/\/doi.org\/10.1111\/dom.13801.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1836_CR44","doi-asserted-by":"publisher","first-page":"286","DOI":"10.4103\/ijem.IJEM_517_16","volume":"21","author":"S Gupta","year":"2017","unstructured":"Gupta S, Shaikh S, Joshi P, Bhure S, Suvarna V. Long-term efficacy and safety of empagliflozin monotherapy in drug-na\u00efve patients with type\u00a02 diabetes in Indian subgroup: results from a 76-week extension trial of phase\u00a0III, double-blind, randomized study. Indian J Endocrinol Metab. 2017;21(2):286\u201392. https:\/\/doi.org\/10.4103\/ijem.IJEM_517_16.","journal-title":"Indian J Endocrinol Metab"},{"issue":"1","key":"1836_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-015-0314-0","volume":"14","author":"M Roden","year":"2015","unstructured":"Roden M, Merker L, Christiansen AV, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-na\u00efve patients with type\u00a02 diabetes: a double-blind extension of a phase\u00a0III randomized controlled trial. Cardiovasc Diabetol. 2015;14(1):154. https:\/\/doi.org\/10.1186\/s12933-015-0314-0.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"1836_CR46","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/dom.12460","volume":"17","author":"NB Amin","year":"2015","unstructured":"Amin NB, Wang X, Jain SM, Lee DS, Nucci G, Rusnak JM. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter\u00a02 inhibitor, in patients with type\u00a02 diabetes on a background of metformin. Diabetes Obes Metab. 2015;17(6):591\u20138. https:\/\/doi.org\/10.1111\/dom.12460.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1836_CR47","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.2337\/dc13-0663","volume":"36","author":"E Ferrannini","year":"2013","unstructured":"Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type\u00a02 diabetes. Diabetes Care. 2013;36(12):4015\u201321. https:\/\/doi.org\/10.2337\/dc13-0663.","journal-title":"Diabetes Care"},{"issue":"12","key":"1836_CR48","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","volume":"56","author":"FJ Lavalle-Gonz\u00e1lez","year":"2013","unstructured":"Lavalle-Gonz\u00e1lez FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type\u00a02 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56(12):2582\u201392. https:\/\/doi.org\/10.1007\/s00125-013-3039-1.","journal-title":"Diabetologia"},{"issue":"12","key":"1836_CR49","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/dom.12185","volume":"15","author":"J Rosenstock","year":"2013","unstructured":"Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter\u00a02 (SGLT2) inhibitor, as add-on to metformin in type\u00a02 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013;15(12):1154\u201360. https:\/\/doi.org\/10.1111\/dom.12185.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1836_CR50","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","volume":"1","author":"M Roden","year":"2013","unstructured":"Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type\u00a02 diabetes: a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet Diabetes Endocrinol. 2013;1(3):208\u201319. https:\/\/doi.org\/10.1016\/S2213-8587(13)70084-6.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1836_CR51","first-page":"174","volume":"17","author":"R Sharma","year":"2025","unstructured":"Sharma R, Verma AK, Tiwari SN. Comparison of empagliflozin and linagliptin in glycaemic control among type\u00a02 diabetes mellitus patients. Int J Curr Pharm Rev Res. 2025;17(3):174\u20138.","journal-title":"Int J Curr Pharm Rev Res"},{"issue":"3","key":"1836_CR52","doi-asserted-by":"publisher","first-page":"183","DOI":"10.47583\/ijpsrr.2024.v84i03.025","volume":"84","author":"S Hameed","year":"2024","unstructured":"Hameed S, Kumar A, Manohar M, Singh A, Mohan L. Efficacy and safety of empagliflozin versus linagliptin as add-on therapy to insulin in patients of chronic kidney disease and type\u00a02 diabetes mellitus: a randomised controlled trial. Int J Pharm Sci Rev Res. 2024;84(3):183\u20139. https:\/\/doi.org\/10.47583\/ijpsrr.2024.v84i03.025.","journal-title":"Int J Pharm Sci Rev Res"},{"issue":"2","key":"1836_CR53","doi-asserted-by":"publisher","first-page":"139","DOI":"10.47583\/ijpsrr.2022.v77i02.022","volume":"77","author":"RB Raman","year":"2022","unstructured":"Raman RB, Kumar D, Roushan R. Comparative study of efficacy and safety of empagliflozin vs linagliptin as add-on therapy to insulin in patients of type\u00a02 diabetes mellitus and chronic kidney disease in tertiary care centre of Eastern India. Int J Pharm Sci Rev Res. 2022;77(2):139\u201345. https:\/\/doi.org\/10.47583\/ijpsrr.2022.v77i02.022.","journal-title":"Int J Pharm Sci Rev Res"},{"issue":"3","key":"1836_CR54","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3760\/cma.j.issn.1674-5809.2019.03.006","volume":"11","author":"L Mou","year":"2019","unstructured":"Mou L, Jiang J, Zhang Y, et al. Comparison of efficacy and safety of dapagliflozin and linagliptin in overweight or obesity type\u00a02 diabetic patients with poor glycemic control of oral antidiabetic drugs. Chin J Diabetes Mellitus. 2019;11(3):190\u20135. https:\/\/doi.org\/10.3760\/cma.j.issn.1674-5809.2019.03.006.","journal-title":"Chin J Diabetes Mellitus"},{"issue":"7","key":"1836_CR55","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type\u00a02 diabetes. N Engl J Med. 2017;377(7):644\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1611925.","journal-title":"N Engl J Med"},{"issue":"9","key":"1836_CR56","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2337\/dc15-0843","volume":"38","author":"AL Peters","year":"2015","unstructured":"Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter\u00a02 inhibition. Diabetes Care. 2015;38(9):1687\u201393. https:\/\/doi.org\/10.2337\/dc15-0843.","journal-title":"Diabetes Care"},{"issue":"1","key":"1836_CR57","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.2040-1124.2011.00184.x","volume":"3","author":"B Ahr\u00e9n","year":"2012","unstructured":"Ahr\u00e9n B. DPP-4 inhibition and islet function. J Diabetes Investig. 2012;3(1):3\u201310. https:\/\/doi.org\/10.1111\/j.2040-1124.2011.00184.x.","journal-title":"J Diabetes Investig"},{"issue":"11","key":"1836_CR58","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1111\/dom.13041","volume":"19","author":"PH Groop","year":"2017","unstructured":"Groop PH, Cooper ME, Perkovic V, et al. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type\u00a02 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes Obes Metab. 2017;19(11):1610\u20139. https:\/\/doi.org\/10.1111\/dom.13041.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1836_CR59","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1053\/j.ajkd.2015.03.024","volume":"66","author":"ME Cooper","year":"2015","unstructured":"Cooper ME, Perkovic V, McGill JB, et al. Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type\u00a02 diabetes. Am J Kidney Dis. 2015;66(3):441\u20139. https:\/\/doi.org\/10.1053\/j.ajkd.2015.03.024.","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"1836_CR60","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1111\/dom.14075","volume":"22","author":"J Liu","year":"2020","unstructured":"Liu J, Li L, Li S, et al. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type\u00a02 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2020;22(9):1619\u201327. https:\/\/doi.org\/10.1111\/dom.14075.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1836_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02733-w","volume":"7","author":"J Liu","year":"2017","unstructured":"Liu J, Li L, Li S, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type\u00a02 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017;7(1):2824. https:\/\/doi.org\/10.1038\/s41598-017-02733-w.","journal-title":"Sci Rep"},{"issue":"4","key":"1836_CR62","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/M18-3136","volume":"171","author":"CV Dave","year":"2019","unstructured":"Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med. 2019;171(4):248\u201356. https:\/\/doi.org\/10.7326\/M18-3136.","journal-title":"Ann Intern Med"},{"issue":"6","key":"1836_CR63","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1099\/00222615-48-6-535","volume":"48","author":"SE Geerlings","year":"1999","unstructured":"Geerlings SE, Brouwer EC, Gaastra W, Verhoef J, Hoepelman AIM. Effect of glucose and pH on uropathogenic and non-uropathogenic Escherichia coli: studies with urine from diabetic and non-diabetic individuals. J Med Microbiol. 1999;48(6):535\u20139. https:\/\/doi.org\/10.1099\/00222615-48-6-535.","journal-title":"J Med Microbiol"},{"issue":"6","key":"1836_CR64","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/s0924-8579(02)00090-0","volume":"19","author":"SE Geerlings","year":"2002","unstructured":"Geerlings SE, Meiland R, Hoepelman AI. Pathogenesis of bacteriuria in women with diabetes mellitus. Int J Antimicrob Agents. 2002;19(6):539\u201345. https:\/\/doi.org\/10.1016\/s0924-8579(02)00090-0.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"1836_CR65","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1517\/14740338.2015.1006625","volume":"14","author":"AJ Scheen","year":"2015","unstructured":"Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type\u00a02 diabetes. Expert Opin Drug Saf. 2015;14(4):505\u201324. https:\/\/doi.org\/10.1517\/14740338.2015.1006625.","journal-title":"Expert Opin Drug Saf"},{"issue":"24","key":"1836_CR66","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type\u00a02 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"issue":"15","key":"1836_CR67","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"11","key":"1836_CR68","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2337\/dc17-1011","volume":"40","author":"GN Nadkarni","year":"2017","unstructured":"Nadkarni GN, Ferrandino R, Chang A, et al. Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis. Diabetes Care. 2017;40(11):1479\u201385. https:\/\/doi.org\/10.2337\/dc17-1011.","journal-title":"Diabetes Care"},{"issue":"1","key":"1836_CR69","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type\u00a02 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69\u201379. https:\/\/doi.org\/10.1001\/jama.2018.18269.","journal-title":"JAMA"},{"issue":"2","key":"1836_CR70","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/dom.13531","volume":"21","author":"CV Dave","year":"2019","unstructured":"Dave CV, Schneeweiss S, Patorno E. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2019;21(2):434\u20138. https:\/\/doi.org\/10.1111\/dom.13531.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1836_CR71","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1111\/dom.13820","volume":"21","author":"IC Lega","year":"2019","unstructured":"Lega IC, Bronskill SE, Campitelli MA, et al. SGLT2 inhibitors and risk of genital mycotic and urinary tract infection: a population-based study of older adults with diabetes. Diabetes Obes Metab. 2019;21(11):2394\u2013404. https:\/\/doi.org\/10.1111\/dom.13820.","journal-title":"Diabetes Obes Metab"},{"issue":"25","key":"1836_CR72","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1161\/CIRCULATIONAHA.118.039177","volume":"139","author":"E Patorno","year":"2019","unstructured":"Patorno E, Pawar A, Franklin JM, et al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care. Circulation. 2019;139(25):2822\u201330. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.039177.","journal-title":"Circulation"},{"issue":"3","key":"1836_CR73","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/dom.14593","volume":"24","author":"E Patorno","year":"2022","unstructured":"Patorno E, Pawar A, Wexler DJ, et al. Effectiveness and safety of empagliflozin in routine care patients: results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes Obes Metab. 2022;24(3):442\u201354. https:\/\/doi.org\/10.1111\/dom.14593.","journal-title":"Diabetes Obes Metab"},{"key":"1836_CR74","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1186","volume":"369","author":"B Pasternak","year":"2020","unstructured":"Pasternak B, Wintzell V, Eliasson B, et al. Use of SGLT2 inhibitors vs DPP-4 inhibitors and risk of serious renal events. BMJ. 2020;369:m1186. https:\/\/doi.org\/10.1136\/bmj.m1186.","journal-title":"BMJ"},{"issue":"7","key":"1836_CR75","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.1111\/dom.16385","volume":"27","author":"DV O'Hara","year":"2025","unstructured":"O\u2019Hara DV, Jardine MJ. A review of the safety of sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2025;27(7):3598\u2013606. https:\/\/doi.org\/10.1111\/dom.16385.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1836_CR76","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/metabo14050264","volume":"14","author":"C Morace","year":"2024","unstructured":"Morace C, Feola T, Rossi F, et al. Ketoacidosis and SGLT2 inhibitors: a narrative review. Metabolites. 2024;14(5):264. https:\/\/doi.org\/10.3390\/metabo14050264.","journal-title":"Metabolites"},{"issue":"1 Suppl 1","key":"1836_CR77","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.2337\/dc25-S011","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. 11. Chronic kidney disease and risk management: standards of care in diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S239\u201351. https:\/\/doi.org\/10.2337\/dc25-S011.","journal-title":"Diabetes Care"},{"issue":"7","key":"1836_CR78","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S2213-8587(20)30130-3","volume":"8","author":"S Kohsaka","year":"2020","unstructured":"Kohsaka S, Lam CSP, Kim DJ, et al. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. Lancet Diabetes Endocrinol. 2020;8(7):606\u201315. https:\/\/doi.org\/10.1016\/S2213-8587(20)30130-3.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"1836_CR79","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1111\/dom.14702","volume":"24","author":"H Cao","year":"2022","unstructured":"Cao H, Liu T, Wang L, Ji Q. Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: a systematic review and network meta-analysis. Diabetes Obes Metab. 2022;24(8):1448\u201357. https:\/\/doi.org\/10.1111\/dom.14702.","journal-title":"Diabetes Obes Metab"}],"updated-by":[{"DOI":"10.1007\/s13300-026-01862-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000}}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01836-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-025-01836-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01836-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:31:07Z","timestamp":1778229067000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-025-01836-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":79,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1836"],"URL":"https:\/\/doi.org\/10.1007\/s13300-025-01836-2","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13300-026-01862-8","URL":"https:\/\/doi.org\/10.1007\/s13300-026-01862-8","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yue Li has nothing to disclose. Jie Chen has nothing to disclose. Yuying Gao has nothing to disclose. Jun Zhang has nothing to disclose. Siqiong Deng has nothing to disclose. Hao Li has nothing to disclose. Xin Zhang has nothing to disclose. Rui Li has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study is a systematic review and meta-analysis of previously published RCTs and did not involve direct participation of human subjects or the collection of identifiable personal data. Therefore, ethical approval and informed consent were not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}